Literature DB >> 7898685

Hepatitis C infection, cryoglobulinemia, and vasculitic neuropathy. Treatment with interferon alfa: case report and literature review.

S L Khella1, S Frost, G A Hermann, L Leventhal, S Whyatt, M A Sajid, S S Scherer.   

Abstract

A patient with mononeuropathy multiplex, hepatitis C viral infection, and mixed cryoglobulinemia had axonal degeneration by EMG and vasculitis of the epineurial vessels on sural nerve biopsy. There was no evidence of viral particles in the nerve by immunofluorescence. Treatment with interferon alfa improved the patient's symptoms and cleared the hepatitis C viral RNA and cryoglobulins from the serum.

Entities:  

Mesh:

Year:  1995        PMID: 7898685     DOI: 10.1212/wnl.45.3.407

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

1.  Sensory neuropathy in patients with cryoglobulin negative hepatitis-C infection.

Authors:  Min-Suk Yoon; Mark Obermann; Christina Dockweiler; Roland Assert; Ali Canbay; Sebastian Haag; Guido Gerken; Hans-Christoph Diener; Zaza Katsarava
Journal:  J Neurol       Date:  2010-08-04       Impact factor: 4.849

2.  Peripheral neuropathy associated with essential mixed cryoglobulinaemia: a role for hepatitis C virus infection?

Authors:  E Apartis; J M Léger; L Musset; M Gugenheim; P Cacoub; O Lyon-Caen; C Pierrot-Deseilligny; J J Hauw; P Bouche
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

3.  Rituximab in cryoglobulinemic peripheral neuropathy.

Authors:  Roberto Cavallo; Dario Roccatello; Elisa Menegatti; Carla Naretto; Franca Napoli; Simone Baldovino
Journal:  J Neurol       Date:  2009-03-05       Impact factor: 4.849

Review 4.  [Vasculitis associated with viral infections].

Authors:  Pascal Cohen; Loïc Guillevin
Journal:  Presse Med       Date:  2004-11-06       Impact factor: 1.228

5.  Therapy for vasculitic neuropathies.

Authors:  Kenneth C Gorson
Journal:  Curr Treat Options Neurol       Date:  2006-03       Impact factor: 3.972

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.